Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoimmunotherapy With Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed NPC
NCT06064097Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2024
- Primary completion
- Mar 2027
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in nasopharyngeal carcinoma (NPC), sponsored by National Cancer Institute. Primary endpoint: Incidence of grade 3 or higher immune-related adverse events. Started Jun 2024; status: recruiting.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06064097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06064097.